1-(2-amino-6-oxo-1H-purin-9-yl)anthracene-9,10-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 蒽
• 英文名称: 1-(2-amino-6-oxo-1H-purin-9-yl)anthracene-9,10-dione
• 化学式: C₁₉H₁₁N₅O₃
• 分子量: 357.3
• InChiKey: BPFMIIQVNIEKBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  27
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF<br/>[FR] TRIOXACARCINES, CONJUGUÉS TRIOXACARCINE-ANTICORPS, ET LEURS UTILISATIONS
  申请人：HARVARD COLLEGE

  公开号：WO2014082065A1

  公开（公告）日：2014-05-30

  Provided herein are trioxacarcin-antibody drug conjugates of Formula (A): and pharmaceutically acceptable salts thereof, comprising at least one instance of the group - L1 -(A-L2 )a-B attached thereto, wherein a is an integer between 1 and 10, inclusive, L1 is absent or is a linking group, A is a moiety formed from the reaction of two complimentary groups (X and Y), L2 is absent or is another linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing these antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin-antibody drug conjugates, novel trioxacarcins without an antibody conjugated thereto, pharmaceutical compositions thereof, and methods of their use and treatment.

  本文提供的是Formula（A）的三氧卡西青霉素-抗体药物偶联物及其药学上可接受的盐，其中至少包括一个-L1-（A-L2）a-B的组合，其中a是1到10之间的整数，L1不存在或是一个连接基团，A是由两个互补基团（X和Y）反应形成的基团，L2不存在或是另一个连接基团，B是抗体或抗体片段。还提供了制备这些抗体药物偶联物的方法，其药学上可接受的组成物，以及其使用和治疗的方法。此外，还提供了三氧卡西青霉素-抗体药物偶联物的前体，未与抗体偶联的新型三氧卡西青霉素，其药学上可接受的组成物，以及其使用和治疗的方法。
• Trioxacarcins, trioxacarcin#antibody conjugates, and uses thereof
  申请人：President and Fellows of Harvard College

  公开号：US10639381B2

  公开（公告）日：2020-05-05

  Provided herein are trioxacarcin-antibody drug conjugates of Formula (A): and pharmaceutically acceptable salts thereof, comprising at least one instance of the group -L1-(A-L2)a-B attached thereto, wherein a is an integer between 1 and 10, inclusive, L1 is absent or is a linking group, A is a moiety formed from the reaction of two complimentary groups (X and Y), L2 is absent or is another linking group, and B is an antibody or antibody fragment. Also provided are methods of preparing these antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the trioxacarcin-antibody drug conjugates, novel trioxacarcins without an antibody conjugated thereto, pharmaceutical compositions thereof, and methods of their use and treatment.

  本文提供的是式 (A) 的三氧羰基霉素-抗体药物共轭物： 及其药学上可接受的盐，包含至少一个连接在其上的基团-L1-(A-L2)a-B 的实例，其中 a 是 1 至 10（包括 10）之间的整数，L1 不存在或为连接基团，A 是由两个互补基团（X 和 Y）反应形成的分子，L2 不存在或为另一个连接基团，B 是抗体或抗体片段。此外，还提供了制备这些抗体-药物共轭物的方法、其药学上可接受的组合物及其使用和治疗方法。此外，还提供了三氧嘧啶-抗体药物共轭物的前体、不含抗体的新型三氧嘧啶、其药用组合物及其使用和治疗方法。
• TRIOXACARCINS, TRIOXACARCIN-ANTIBODY CONJUGATES, AND USES THEREOF
  申请人：President and Fellows of Harvard College

  公开号：EP2922575A1

  公开（公告）日：2015-09-30
• US9775915B2
  申请人：——

  公开号：US9775915B2

  公开（公告）日：2017-10-03